Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Self-sampling for cervical cancer screening could make testing easier and more accessible

NCT ID NCT05092022

Diagnosis Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study tests whether offering a self-sampling HPV test at a clinic increases the number of women who get screened for cervical cancer. Women who are due for screening can choose between a self-sampled test, a clinician-sampled test, or no screening. The study measures how many women accept and complete the self-sampled test, and whether overall screening rates improve.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Evalyn Self-Sampling Brush
What this could lead to
If successful, offering self-sampling could make cervical cancer screening more accessible and convenient, potentially increasing screening rates and catching more cases early.
What could go wrong
This is a small, single-site study with only 50 participants, so results may not apply broadly. Self-sampling may not be as accurate as clinician-sampled tests, and some women may still prefer the standard method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible but out-of-date for cervical cancer screening * Able to speak, read, and communicate well in English or Spanish * Not at greater than average risk for cervical cancer Exclusion Criteria: * Pregnant * Incarcerated * Greater than average risk for cervical cancer, for example: * Already diagnosed with high-grade precancerous cervical cancer or cervical lesions * Has a compromised immune system * Unable to speak, read, and communicate well in English or Spanish * Unable or unwilling to give implied consent or otherwise complete study requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer screening are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Uterine Cervical Neoplasms cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer screening

Contacts and locations

Locations

  • Penn State Health St. Joseph's

    Reading, Pennsylvania, 19605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.